Clinical trial
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
NCT00235794 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00235794 |
|---|---|
| Title | An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients |
| Official title | An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Enrollment | 50 |
| Start date | Jan 1, 2004 |
| Completion | Sep 1, 2007 |
| First posted | Oct 10, 2005 |
| Last update posted | Dec 27, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: